Please try another search
TORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
MELBOURNE, Australia, April 7, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a clinical-stage biotechnology company specialising in cell therapeutics, is...
Investing in Oncology Forum 2024Van Lanschot Kempen Life Sciences Conference Swiss Biotech Day 2024LSX World Congress MADRID, Spain and BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Oryzon Genomics,...
Aridis Pharmaceuticals (ARDS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one...
As of late, it has definitely been a great time to be an investor in Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) . The stock has moved higher by 31.7% in the past month, while it is also above its 20...
Athersys (O:ATHX) is developing off-the-shelf multipotent adult progenitor cells (MAPCs) to treat a variety of indications, with ischemic stroke, acute myocardial infarction (AMI) and acute...
Instrument Type
Region
Sector
Industry
Date
Category
Provider